Abstract IA16: Mapping metabolic drivers of cancer using chemoproteomic and metabolomic platforms

Abstract

Abstract Cancer cells possess fundamentally altered cellular metabolism that not only leads to a re-wiring of cellular biochemistry, but also drives nearly every aspect of cancer cell pathogenicity. While targeting dysregulated metabolism is a promising strategy for cancer treatment, much of cancer metabolism has focused on well-understood metabolic pathways in central carbon metabolism (e.g. glycolytic or glutamine metabolism) underlying cellular transformation and early-stages of cancer, and has largely ignored many of cellular metabolic pathways or those networks involved in cancer progression, despite clear genetic or metabolic evidence of their involvement in cancer. Here, we describe chemoproteomic and metabolomic technologies that we have utilized to identifying unique and novel dysregulated metabolic drivers of cancer. In particular, we have identified several unique nodes within lipid and sialic acid metabolism that are essential in driving cancer pathogenicity. Citation Format: Daniel Nomura. Mapping metabolic drivers of cancer using chemoproteomic and metabolomic platforms. [abstract]. In: Proceedings of the AACR Special Conference: Metabolism and Cancer; Jun 7-10, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(1_Suppl):Abstract nr IA16.